Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals.
Hanmi will continue its global Phase II trial in SBS while Lilly will further clinical development using available data. Credit: Premreuthai / Shutterstock.com.
Eli Lilly and Company has entered a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), worldwide excluding Korea.
The agreement covers Hanmi’s candidate that uses its LAPSCOVERY long-acting platform technology. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
